Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19

Translated title of the contribution: Hemoperfusion with the Cytosorb device in a patient with severe COVID-19

César Mercado Ferrer, Emilio Rey Vela, Jorge Rico Fontalvo, Rodrigo Daza Arnedo, Nehomar Pájaro Galvis, Greisy González, Jaime Gómez Ayala, Víctor Leal Martínez, Emilio Abuabara Franco, Alonso Pomares Lara, Christian Pérez Calvo, María Raad Sarabia

Research output: Articles / NotesScientific Articlepeer-review


The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded.

Translated title of the contributionHemoperfusion with the Cytosorb device in a patient with severe COVID-19
Original languageSpanish
Article numbere515
JournalRevista Colombiana de Nefrologia
Issue number1
StatePublished - 2021
Externally publishedYes


Dive into the research topics of 'Hemoperfusion with the Cytosorb device in a patient with severe COVID-19'. Together they form a unique fingerprint.

Cite this